4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Announces First Quarter 2026 Financial Results and Reaffirms Guidance
Collard Amendment - CEO Craig Collard's Employment Agreement Updated
Announces Fourth Quarter and Full-Year 2025 Financial Results
Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
Announces Q3 2025 Financial Results and Highlights Commercial Progress
Changes in Board, Management or Compensation, Reg. FD
Stockholders Approve Share Issuance at Heron Therapeutics Meeting
News
Q1
FY 2024
Q3
Q2
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload